These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 11840287

  • 1. Effect of methotrexate polyglutamates on thioguanine nucleotide concentrations during continuation therapy of acute lymphoblastic leukemia with mercaptopurine.
    Dervieux T, Hancock M, Evans W, Pui CH, Relling MV.
    Leukemia; 2002 Feb; 16(2):209-12. PubMed ID: 11840287
    [Abstract] [Full Text] [Related]

  • 2. The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia.
    Adam de Beaumais T, Dervieux T, Fakhoury M, Medard Y, Azougagh S, Zhang D, Yakouben K, Jacqz-Aigrain E.
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):653-8. PubMed ID: 20033410
    [Abstract] [Full Text] [Related]

  • 3. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.
    Nielsen SN, Grell K, Nersting J, Abrahamsson J, Lund B, Kanerva J, Jónsson ÓG, Vaitkeviciene G, Pruunsild K, Hjalgrim LL, Schmiegelow K.
    Lancet Oncol; 2017 Apr; 18(4):515-524. PubMed ID: 28258828
    [Abstract] [Full Text] [Related]

  • 4. Use of allopurinol in children with acute lymphoblastic leukemia to reduce skewed thiopurine metabolism.
    Brackett J, Schafer ES, Leung DH, Bernhardt MB.
    Pediatr Blood Cancer; 2014 Jun; 61(6):1114-7. PubMed ID: 24376133
    [Abstract] [Full Text] [Related]

  • 5. The association between fasting hypoglycemia and methylated mercaptopurine metabolites in children with acute lymphoblastic leukemia.
    Melachuri S, Gandrud L, Bostrom B.
    Pediatr Blood Cancer; 2014 Jun; 61(6):1003-6. PubMed ID: 24415675
    [Abstract] [Full Text] [Related]

  • 6. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology.
    Schmiegelow K, Schrøder H, Gustafsson G, Kristinsson J, Glomstein A, Salmi T, Wranne L.
    J Clin Oncol; 1995 Feb; 13(2):345-51. PubMed ID: 7531219
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine.
    Erb N, Harms DO, Janka-Schaub G.
    Cancer Chemother Pharmacol; 1998 Feb; 42(4):266-72. PubMed ID: 9744770
    [Abstract] [Full Text] [Related]

  • 8. A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia.
    Panetta JC, Yanishevski Y, Pui CH, Sandlund JT, Rubnitz J, Rivera GK, Ribeiro R, Evans WE, Relling MV.
    Cancer Chemother Pharmacol; 2002 Nov; 50(5):419-28. PubMed ID: 12439601
    [Abstract] [Full Text] [Related]

  • 9. A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group).
    Bell BA, Brockway GN, Shuster JJ, Erdmann G, Sterikoff S, Bostrom B, Camitta BM, Pediatric Oncology Group study (now The Children's Oncology Group).
    Pediatr Blood Cancer; 2004 Aug; 43(2):105-9. PubMed ID: 15236274
    [Abstract] [Full Text] [Related]

  • 10. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia.
    Schmiegelow K, Björk O, Glomstein A, Gustafsson G, Keiding N, Kristinsson J, Mäkipernaa A, Rosthøj S, Szumlanski C, Sørensen TM, Weinshilboum R.
    J Clin Oncol; 2003 Apr 01; 21(7):1332-9. PubMed ID: 12663723
    [Abstract] [Full Text] [Related]

  • 11. Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia.
    Dervieux T, Hancock ML, Pui CH, Rivera GK, Sandlund JT, Ribeiro RC, Boyett J, Evans WE, Relling MV.
    Clin Pharmacol Ther; 2003 Jun 01; 73(6):506-16. PubMed ID: 12811360
    [Abstract] [Full Text] [Related]

  • 12. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.
    Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui CH, Evans WE.
    J Natl Cancer Inst; 1999 Dec 01; 91(23):2001-8. PubMed ID: 10580024
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study.
    Balis FM, Holcenberg JS, Poplack DG, Ge J, Sather HN, Murphy RF, Ames MM, Waskerwitz MJ, Tubergen DG, Zimm S, Gilchrist GS, Bleyer WA.
    Blood; 1998 Nov 15; 92(10):3569-77. PubMed ID: 9808549
    [Abstract] [Full Text] [Related]

  • 14. DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma.
    Hedeland RL, Hvidt K, Nersting J, Rosthøj S, Dalhoff K, Lausen B, Schmiegelow K.
    Cancer Chemother Pharmacol; 2010 Aug 15; 66(3):485-91. PubMed ID: 19956952
    [Abstract] [Full Text] [Related]

  • 15. Myelotoxicity, pharmacokinetics, and relapse rate with methotrexate/6-mercaptopurine maintenance therapy of childhood acute lymphoblastic leukemia.
    Schmiegelow K, Ifversen M.
    Pediatr Hematol Oncol; 1996 Aug 15; 13(5):433-41. PubMed ID: 10897815
    [Abstract] [Full Text] [Related]

  • 16. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.
    Relling MV, Hancock ML, Boyett JM, Pui CH, Evans WE.
    Blood; 1999 May 01; 93(9):2817-23. PubMed ID: 10216075
    [Abstract] [Full Text] [Related]

  • 17. Metabolites of mercaptopurine in red blood cells: a relationship between 6-thioguanine nucleotides and 6-methylmercaptopurine metabolite concentrations in children with lymphoblastic leukemia.
    Chrzanowska M, Kolecki P, Duczmal-Cichocka B, Fiet J.
    Eur J Pharm Sci; 1999 Aug 01; 8(4):329-34. PubMed ID: 10425383
    [Abstract] [Full Text] [Related]

  • 18. Methotrexate and its polyglutamate derivatives in erythrocytes during and after weekly low-dose oral methotrexate therapy of children with acute lymphoblastic leukemia.
    Schrøder H, Fogh K.
    Cancer Chemother Pharmacol; 1988 Aug 01; 21(2):145-9. PubMed ID: 2450690
    [Abstract] [Full Text] [Related]

  • 19. Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia.
    Nielsen SN, Grell K, Nersting J, Frandsen TL, Hjalgrim LL, Schmiegelow K.
    Cancer Chemother Pharmacol; 2016 Nov 01; 78(5):983-994. PubMed ID: 27600880
    [Abstract] [Full Text] [Related]

  • 20. Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia.
    Vang SI, Schmiegelow K, Frandsen T, Rosthøj S, Nersting J.
    Cancer Chemother Pharmacol; 2015 May 01; 75(5):1089-93. PubMed ID: 25788208
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.